Opendata, web and dolomites


An integrated high-throughput human cell and Drosophila screening platform for the expedited discovery of anti-ageing compounds

Total Cost €


EC-Contrib. €






 AgePhagy project word cloud

Explore the words cloud of the AgePhagy project. It provides you a very rough idea of what is the project "AgePhagy" about.

age    modifiers    soon    elderly    outcome    autophagy    collaborator    validate    organisms    ageing    sought    clock    assays    healthy    geroprotector    uncover    connecting    degradation    dna    innovative    primary    accelerated    maximise    industrial    vitro    drugs    longevity    detects    human    commercial    library    modifier    upregulation    combine    closely    ucl    business    subtle    genetic    cells    cellular    model    discovery    collaborate    cancerphagy    drosophila    anti    accurately    compounds    grant    decades    trametinib    assure    platform    transition    gsk    biomarker    rapamycin    viability    clinical    final    ultimate    population    clocks    steeply    economic    profound    drug    trials    impactful    replicating    accompanying    methylation    cellage    first    instance    health    expedited    lived    pharmacological    launch    shown    treatment    designed    epigenetic    outputs    vivo    showed    mimic    societal    differentiates    diseases    lifespan    mutants   

Project "AgePhagy" data sheet

The following table provides information about the project.


Organization address
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙872 €
 EC max contribution 149˙872 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 149˙872.00


 Project objective

The steeply increasing ageing population, and accompanying rise of age-related diseases will soon have profound societal and economic effects, making ageing research increasingly important and outcome of this grant impactful. Our most promising way to improve health in the elderly is by replicating decades of genetic finding in model organisms of healthy long-lived mutants to pharmacological approaches. This will enable transition of these findings to clinical trials. In the CancerPhagy project, we showed that genetic upregulation of autophagy, major cellular degradation pathway, increased lifespan, which we aim to mimic by pharmacological treatment. To this end, we developed the CellAge epigenetic clock, which is based on DNA methylation and which is the first clock that accurately detects subtle ageing changes in human primary cells in vitro upon a short anti-ageing drugs treatment, as shown using rapamycin and trametinib. This differentiates our clock from other available epigenetic clocks which are designed to accurately determine human age in years. By connecting the CellAge clock to autophagy drug library we will test the commercial viability of our anti-ageing drug assessment platform. To further validate our CellAge clock as a robust human ageing biomarker, we will combine its outputs with longevity assays in vivo in Drosophila. The final outcome will be an innovative and accelerated discovery platform for sought after anti-ageing/geroprotector drugs, which we will in this first instance test autophagy modifier drugs. Throughout the project we will closely collaborate with our industrial collaborator, GSK and UCL Business, which will assure we maximise the potential of our platform. Our ultimate goal is to uncover novel autophagy modifiers with anti-ageing properties and to launch the CellAge clock as the most advanced platform for expedited discovery of anti-ageing compounds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGEPHAGY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGEPHAGY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More